title: Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity.
abstract: BACKGROUND
  Patients with active acromegaly have increased bone turnover and skeletal abnormalities. Biochemical cure of acromegaly may represent a functional GH-deficient state and result in cortical bone loss. Reduced PTH target-organ sensitivity occurs in adult GH deficiency and may underlie the associated development of osteoporosis.
  
  
  OBJECTIVE
  We examined the effect of active and treated acromegaly on PTH concentration and target-organ sensitivity.
  
  
  METHODS
  Ten active acromegalic subjects (GH nadir > 0.3 mug/liter after 75-g oral glucose load and IGF-I above age-related reference range) and 10 matched controls participated in the study.
  
  
  METHODS
  Half-hourly blood and 3-h urine samples were collected on patients and controls for 24 h. Samples were analyzed for PTH, calcium (Ca), nephrogenous cAMP (NcAMP, a marker of PTH renal activity), beta C-telopeptide (bone resorption marker), and procollagen type-I amino-terminal propeptide (bone formation marker). Serum calcium was adjusted for albumin (ACa). Eight acromegalic subjects who achieved biochemical cure (GH nadir < 0.3 mug/liter after 75-g oral glucose load and IGF-I within reference range) after standard surgical and/or medical treatment reattended and the protocol repeated.
  
  
  RESULTS
  Active acromegalic subjects had higher 24-h mean PTH, NcAMP, ACa, urine Ca, beta C-telopeptide, and procollagen type I amino-terminal propeptide (P < 0.05), compared with controls. Twenty-four-hour mean PTH increased (P < 0.001) in the acromegalic subjects after treatment, whereas NcAMP and ACa decreased (P < 0.05).
  
  
  CONCLUSIONS
  Increased bone turnover associated with active acromegaly may result from increased PTH concentration and action. Biochemical cure of acromegaly results in reduced PTH target-organ sensitivity indicated by increased PTH with decreased NcAMP and ACa concentrations. PTH target-organ sensitivity does not appear to return to normal after successful treatment of acromegaly in the short term and may reflect functional GH deficiency.
authors.affiliation: Department of Diabetes and Endocrinology, Link 7C, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, United Kingdom. h.white@ukf.net
authors.forename: H D
authors.initials: HD
authors.lastname: White
authors.forename: A M
authors.initials: AM
authors.lastname: Ahmad
authors.forename: B H
authors.initials: BH
authors.lastname: Durham
authors.forename: S
authors.initials: S
authors.lastname: Chandran
authors.forename: A
authors.initials: A
authors.lastname: Patwala
authors.forename: W D
authors.initials: WD
authors.lastname: Fraser
authors.forename: J P
authors.initials: JP
authors.lastname: Vora
mesh_terms: D000172:Acromegaly / Q000503:physiopathology* / Q000532:radiotherapy / Q000601:surgery; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002940:Circadian Rhythm / Q000502:physiology*; D000242:Cyclic AMP / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood* / Q000652:urine; D012016:Reference Values
chemical_list: D015415:Biomarkers; D010281:Parathyroid Hormone; D000242:Cyclic AMP